News

Ascent Scientific has announced the availability of the first commercial source of TMCB – a new kinase inhibitor that is selective for CK2. It is more selective than

Oncolytics Biotech (Oncolytics) has reported that it has been granted its 32nd US Patent no 7582289, entitled ‘Viruses for the Treatment of Cellular Proliferative Disorders.’ The patent claims

Cell Biosciences has launched a service program to provide phosphoprotein analysis of pre-clinical samples for pharmaceutical and biotechnology companies. Under the Cell Biosciences Focus Assay Service program, client

Zealand Pharma has reported that it is developing a new treatment, ZP2929, for Type 2 Diabetes. ZP2929 has the potential to significantly decrease body weight and reduce the

Novavax has reported positive results from a phase II human clinical trial of its trivalent seasonal influenza virus-like particle (VLP) vaccine candidate. The vaccine was well tolerated and

Sanofi Pasteur has reported that United Nations agency has awarded contracts to Shantha Biotechnics (Shantha) for supplies of pentavalent vaccine SHAN5 (combination vaccine of Diphtheria, Pertussis, Tetanus, Haemophilus

Icagen has reported top line results of a randomized, double-blind, placebo-controlled, proof-of-mechanism phase IIa study of senicapoc in allergic asthma. Senicapoc reduced the late asthmatic response (LAR) to

SynCo Bio Partners has signed a contract to manufacture a live biotherapeutic with a Japanese pharmaceutical company. The undisclosed company’s product is a live biotherapeutic based anticancer drug.

Basilea Pharmaceutica ( Basilea) has reported that the FDA has accepted the complete response submitted by the Johnson & Johnson. The Complete Response submission addresses the FDA Complete